Company

scPharmaceuticals, Inc.

Burlington, US biopharmaceutical company commercializing FUROSCIX, an injectable furosemide for heart failure and chronic kidney disease.

About

Founded in 2014 and headquartered in Burlington, US, scPharmaceuticals, Inc. develops and commercializes cardiorenal products, mainly FUROSCIX, an injectable formulation of furosemide for patients with heart failure and chronic kidney disease. It sells directly to healthcare providers and institutions. The company reported net revenue of USD 36.33 mn for 2024. It has raised USD 50.00 mn in total, and its most recent round was a private placement and follow-on in November 2017. John Tucker is CEO, alongside Pieter Muntendam.

3Funding rounds

4Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in